Overview Request Sample Pages Request Customization Download PDF
You are viewing: Australia Biochips Market analysis
Part of: Biochips Market (Global)

The Australia Biochips Market was valued at $193.4 Million in 2025 and projected to reach to $273.3 Million by 2030, representing a compound annual growth rate of 7.2%. Australia's biochips market is positioned for sustained growth through 2030, driven by increasing healthcare digitalization and diagnostic innovation.

Australia Biochips Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Biochips Market Trends and Insights

  • Australia is establishing itself as a key player in the Asia Pacific biochips sector, driven by advances in diagnostic technologies and personalized medicine adoption.
  • The Australian healthcare system's emphasis on innovation and research infrastructure supports the expansion of biochip applications across clinical diagnostics, drug discovery, and genomic analysis. The 7.2% compound annual growth rate reflects Australia's commitment to biotechnology development and increasing investment in point-of-care testing solutions.
  • Australia's regulatory environment and strong academic research institutions are accelerating biochip commercialization and clinical deployment.
  • Between 2025 and 2030, Australia is expected to see heightened demand for lab-on-chip technologies and microfluidic devices, positioning the country as a regional innovation hub within Asia Pacific..

Key Market Statistics

  • CAGR (2025-2030) 7.2% CAGR
  • Market Size, 2025 ~USD 193.4 Million
  • Forecast, 2030 ~USD 273.3 Million
  • Country Australia

Australia Biochips Market Overview

Market Valuation Growth :

Australia's biochips market is valued at USD 193.4 million in 2025, with a projected CAGR of 7.2% through 2030, reaching USD 273.3 million. This steady growth reflects increasing adoption of advanced diagnostic technologies across Australian healthcare institutions.

Asia Pacific Leadership Position :

Australia is emerging as a key regional player in the Asia Pacific biochips sector, leveraging its robust research infrastructure and healthcare innovation ecosystem. The country's strategic position supports both domestic market expansion and regional export opportunities.

Personalized Medicine Adoption :

Australian healthcare providers are increasingly integrating personalized medicine approaches, driving demand for biochip technologies. This shift is supported by government initiatives promoting precision health and genomic medicine implementation across major medical centers.

Research & Innovation Infrastructure :

Australia's world-class research institutions and healthcare system emphasis on innovation create a favorable environment for biochip development and commercialization. Strong university-industry partnerships accelerate technology adoption and market penetration.

Australia Biochips Market Dynamics

  • The Australian healthcare system's commitment to precision medicine and advanced diagnostics creates strong demand for biochip solutions.
  • Government support for medical research and private sector investment in healthcare technology further strengthen market fundamentals. The market will benefit from growing adoption among major hospitals, diagnostic laboratories, and research institutions across major cities including Sydney, Melbourne, and Brisbane.
  • Regulatory frameworks supporting medical device innovation and increasing healthcare expenditure provide additional growth catalysts.
  • Australia's aging population and rising chronic disease prevalence will continue to drive demand for advanced diagnostic biochip technologies through the forecast period..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Australia's biochips market is valued at USD 193.4 million in 2025, with a projected value of USD 273.3 million by 2030.
      • Australia is experiencing a 7.2% CAGR, reflecting strong adoption of diagnostic and personalized medicine technologies.
      • Australia's research institutions and regulatory framework are driving biochip innovation and commercialization across the region.
      • Point-of-care testing and lab-on-chip technologies are key growth drivers in Australia's biochips market through 2030.

      Biochips Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MICROFLUIDICS (Fabrication Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 8.8% from 2025 to 2030
      Largest Segment MICROARRAYS (Fabrication Technology)
      Market Size Base Year (Billions) ~USD 14.01 (2025)
      Revenue Forecast (Billions) ~USD 21.36 (2030)
      Segments Covered Products & Services, Type, Application, Fabrication Technology, End User, Product & Service

      Australia Biochips Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Products & Services

      • Consumables
      • Instruments
      • Software & Services

      By Type

      • Cell Arrays
      • Dna Chips
      • Lab-On-A-Chip
      • Protein Chips
      • Tissue Arrays

      By Application

      • Agricultural Biotechnology
      • Cancer Diagnosis & Treatment
      • Clinical Diagnostic
      • Diagnostics
      • Drug Discovery
      • Expression Profiling
      • Gene Expression
      • Genomics
      • High-Throughput Screening
      • Ivd & Poc
      • Other Dna Chip Applications
      • Other Loac Applications
      • Other Protein Chip Applications
      • Proteomics
      • Snp Genotyping

      By Fabrication Technology

      • Microarrays
      • Microfluidics

      By End User

      • Academic & Research Institutes
      • Biotechnology & Pharmaceutical Companies
      • Contract Research Organizations
      • Hospitals & Diagnostic Centers
      • Other End Users

      By Product & Service

      • Consumables
      • Instruments
      • Software & Services

      AUSTRALIA: BIOCHIPS MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES17.518.619.921.222.624.125.727.56.7
      BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES91.398.2105.6113.6122.3131.7142153.27.7
      CONTRACT RESEARCH ORGANIZATIONS10.711.712.613.714.916.217.619.18.6
      HOSPITALS & DIAGNOSTIC CENTERS373941.243.545.948.551.354.35.7
      OTHER END USERS12.513.314.115161718.119.26.3
      TOTAL169.1180.8193.4207221.5237.4254.6273.37.2

      Target Audience

      • Biochip Manufacturers & Technology Providers : Need Australia-specific market data to assess market entry viability, size distribution channels, and identify key customer segments within Australian healthcare institutions and diagnostic laboratories.
      • Healthcare Investment Firms & Venture Capitalists : Require detailed Australian market forecasts and growth drivers to evaluate investment opportunities in biochip startups, diagnostic companies, and healthcare technology ventures operating in the region.
      • Diagnostic Laboratory Networks & Hospital Systems : Need market intelligence on biochip adoption trends, competitive offerings, and technology roadmaps to inform procurement decisions and strategic technology integration planning for Australian facilities.
      • Medical Device Distributors & Importers : Require Australia-specific market sizing and growth projections to optimize inventory planning, identify emerging product categories, and develop distribution partnerships with local healthcare providers.
      • Government & Healthcare Policy Organizations : Need comprehensive market data on biochip adoption and innovation trends to inform healthcare policy, research funding priorities, and regulatory frameworks supporting precision medicine advancement in Australia.

      Key Companies in the Australia Biochips Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects,
      JABILUnited StatesPublic CompanyRegulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem),
      AT&SCanadaPublic CompanyTurnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration,
      X-FABBelgiumPublic CompanyAutomotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes),
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other,
      10X GENOMICSUnited StatesPublic CompanyChromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents),
      CEPHEIDUnited StatesPrivate CompanyGeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics),
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
      REVVITYUnited StatesPublic CompanyDiagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions,

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.

      JABIL

      Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.

      AT&S

      AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      X-FAB

      X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.

      GE HEALTHCARE

      GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.

      QIAGEN

      Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ABBOTT

      Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.

      STANDARD BIOTOOLS

      Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.

      10X GENOMICS

      10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.

      CEPHEID

      Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.

      BIOMéRIEUX

      bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.

      REVVITY

      Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise valuation data for Australia's biochips market with country-specific CAGR of 7.2%, enabling accurate financial planning and investment decisions tailored to the Australian market landscape.
      • Regional Competitive Intelligence : Understand Australia's position within the Asia Pacific biochips sector and identify competitive advantages. Benchmark against regional peers and capitalize on Australia's emerging leadership in diagnostic innovation.
      • Localized Growth Drivers Analysis : Gain insights into Australia-specific factors driving market growth including personalized medicine adoption, healthcare system innovation priorities, and research infrastructure investments shaping demand.
      • Strategic Market Entry Planning : Develop targeted go-to-market strategies for Australia with detailed understanding of local healthcare adoption patterns, regulatory environment, and key institutional buyers in major metropolitan areas.
      • Investment & Partnership Opportunities : Identify high-potential segments and stakeholders within Australia's biochips ecosystem, including research institutions, diagnostic laboratories, and healthcare providers driving technology adoption.

      Frequently asked questions

      What is the current size of Australia's biochips market?

      Australia's biochips market is valued at USD 193.4 million in 2025 and is projected to grow to USD 273.3 million by 2030.

      What is the growth rate of Australia's biochips market?

      Australia's biochips market is growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2030.

      What are the main applications driving Australia's biochips market?

      Key applications in Australia include clinical diagnostics, drug discovery, genomic analysis, and point-of-care testing solutions.

      Which factors are supporting biochip adoption in Australia?

      Australia's strong research institutions, supportive regulatory environment, and emphasis on personalized medicine are key growth drivers.

      How does Australia's biochips market compare to the Asia Pacific region?

      Australia is establishing itself as a regional innovation hub within Asia Pacific, with a 7.2% CAGR supporting its position as a key biochips market.

      RESEARCH METHODOLOGY

      This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

      Secondary Research

      This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

      Primary Research

      In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.

      A breakdown of the primary respondents is provided below:

      Biochips Market

      Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

      Note 2: Other designations include sales, marketing, and product managers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

      Biochips Market

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

      Market Definition

      The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.

      Stakeholders

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Research Institutes
      • Academic Institutes
      • Contract Research Organizations
      • Research and Consulting Companies
      • Biochip Manufacturers and Distributors
      • DNA & Gene Chip Manufacturers and Distributors
      • Protein Microarray Manufacturers and Distributors
      • Lab-on-a-Chip Manufacturers and Distributors
      • Cell & Tissue Array Manufacturers and Distributors

      Report Objectives

      • To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
      • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

       

      Get the Full Biochips Market Report

      Full forecast, segment splits, and company analysis for all Biochips Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status